TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05463055

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Therapy System (ProBeam)
Description: All of subjects (tumor patients, including tumors of the nervous system, head and neck, chest, abdomen, spine, pelvic cavity, limbs and other tumors) will be treated with Proton radiation therapy using the medical device Varian ProBeam Proton Therapy System (ProBeam). The screening period from informed consent to enrollment is expected to be 4 weeks, while the treatment period is 1 to 8 weeks. The period after the last treatment is divided into short-term follow-up and long-term follow-up, in which short-term follow-up will be 3 months after the end of the last treatment. Total expected participation for each subject from screening to the completion of short-term follow-up is a maximum duration of 12 weeks + 3 months ( for this trial). Long-term follow-up continues after the end of short-term follow-up until the 5th year after the end of the last radiotherapy session.
Study: NCT05215847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARD-101
Description: Twice daily, oral administration
Study: NCT05299970

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fermented porridge
Description: A millet porridge (fermented or not, depending on group allocation) serving will be provided to participants daily, for consumption. consumption will be directly observed.
Study: NCT05983302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma-Fibrin Glue
Description: The first intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone PRP-FG intervention for 8 weeks.
Study: NCT05299970

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fermented porridge
Description: A millet porridge (fermented or not, depending on group allocation) serving will be provided to participants daily, for consumption. consumption will be directly observed.
Study: NCT06062576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yunnan Baiyao
Description: On the basis of the optimal clinical treatment scheme, Yunnan Baiyao powder or ointment was used to treat the wound for 2 weeks
Study: NCT05080543

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albumin 20% and terlipressin
Description: Evaluation the effect of adding 20% HSA and terlipressin on microvascular ﬂow index (MFI), flow heterogeneity index, total vessel density (TVD), and perfused vessel density (PVD) in comparison to the standard care in patient with septic shock.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin 20% and terlipressin
Description: Evaluation the effect of adding 20% HSA and terlipressin on microvascular ﬂow index (MFI), flow heterogeneity index, total vessel density (TVD), and perfused vessel density (PVD) in comparison to the standard care in patient with septic shock.
Study: NCT05286684

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Consultation
Description: History of the disease, anatomopathological and molecular biological data concerning the initial tumor; Collection of treatments received and/or in progress by the patient for her meningeal tumor (chemotherapy, targeted therapy, radiotherapy, surgery, corticosteroids, antiepileptics); Evaluation of the general condition and neurological status.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cerebral and medullary MRI, lumbar puncture, CSF sampling
Description: diagnosis of leptomeningeal involvement

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: biological test
Description: 5 ml of additional CSF after diagnostic lumbar puncture for proteomic analysis, 50-100 µl of breast aspiration fluid (NAF) for patients with an existing breast tumor, for proteomic analysis 10 ml of blood for proteomic analysis
Study: NCT06169423

Intervention type: OTHER
Group type: OTHER
Intervention: Educative intervention
Description: an activity for simulation-based learning First, a theoretical session was carried out in order to acquire theoretical knowledge, skills to provide support for perinatal grief, and improve self-awareness. Prior to this, a pre-questionnaire was carried out in order to previously evaluate these aspects.~Subsequently, a first session was held to make contact with the simulation, teach the scenarios, material, etc. After this, two questionnaires were passed: one related to the acquisition of knowledge, skills to provide support, self-awareness and another on the students' satisfaction with the simulation.
Study: NCT05107934

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RPH-104
Description: solution for subcutaneous injection, 40 mg/mL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Sodium Chloride solution for Injection
Study: NCT05803499

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted Cognitive Behavior Therapy for Insomnia
Description: This intervention consists of six, 50-min. online individual sessions delivered via video conference. Content was developed by tailoring standard cognitive behavioral therapy for insomnia (CBT-I) to the specific needs of people who recently lost spouses/long-term partners, by using qualitative data gathered in focus groups. The intervention incorporates key concepts of CBT-I (sleep restriction; stimulus control) and positive emotion psychology (everyday mindfulness; gratitude and self-compassion). Individualized sleep plans (including weekly sleep windows) will be created for intervention participants, and each weekly session will involve a discussion about participants' progress in improving sleep disturbance. Support and recommended coping skills for loss and bereavement will also be provided.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Information-Only Control
Description: The control session (approx. 50-min. in length) will be delivered online in a one-to-one format (participant and facilitator) via videoconference. Educational brochures based on recommendations provided by the American Academy of Sleep Medicine focused on sleep and health and sleep hygiene education will be used. No specific or individualized recommendations will be given to control participants.
Study: NCT05826158

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 18FmFBG imaging on the Large Field of View PET/CT (Total body PET/CT)
Description: 18F-mFBG imaging on the Large Field of View PET/CT (Total body PET/CT)
Study: NCT04914416

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T16
Description: Verum T16 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and/or blackcurrant extract) with white kidney bean extract, and Zinc. Daily dosage is 1000 mg in 3 capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T16
Description: Verum T16 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and/or blackcurrant extract) with white kidney bean extract, and Zinc. Daily dosage is 1000 mg in 3 capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Verum T16
Description: Verum T16 is a polyphenol mix extract ( olive leaf, pomelo, pomegranate, and/or blackcurrant extract) with white kidney bean extract, and Zinc. Daily dosage is 1000 mg in 3 capsules.
Study: NCT04202211

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FMT oral
Description: lyophilized FMT given orally (10 capsules) twice weekly for total of 8 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FMT oral
Description: lyophilized FMT given orally (10 capsules) twice weekly for total of 8 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FMT enema
Description: lyophilized FMT given via enema (1) twice weekly for total of 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral
Description: placebo given orally (10 capsules) twice weekly for total of 8 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo enema
Description: placebo given via enema (1) twice weekly for total of 8 weeks
Study: NCT04202211

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo enema
Description: placebo given via enema (1) twice weekly for total of 8 weeks
Study: NCT04885712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin≥1000mg
Description: Subjects take the investigational products once a day for 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin≥1000mg
Description: Subjects take the investigational products once a day for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin≥1000mg
Description: Subjects take the investigational products once a day for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15mg
Description: Subjects take the investigational products once a day for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg
Description: Subjects take the investigational products once a day for 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone 15mg Placebo
Description: Subjects take the investigational products once a day for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15mg Placebo
Description: Subjects take the investigational products once a day for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30mg Placebo
Description: Subjects take the investigational products once a day for 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone 30mg Placebo
Description: Subjects take the investigational products once a day for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg
Description: Subjects take the investigational products once a day for 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg
Description: Subjects take the investigational products once a day for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg
Description: Subjects take the investigational products once a day for 24 weeks.
Study: NCT05014230

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Open Placebo
Description: Zeebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opioid medication as part of standard care
Description: Opioid medication as prescribed by prescriber. This is not impacted by being in the research study.

Intervention type: OTHER
Group type: OTHER
Intervention: Opioid medication as part of standard care
Description: Opioid medication as prescribed by prescriber. This is not impacted by being in the research study.
Study: NCT05071833

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Peppermint oil.
Description: Peppermint oil.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06066931

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plastic surgery of the pelvic floor and perineal wound with counter-displaced skin-subcutaneous fascial flaps after extralevatory abdominal-perineal extirpation of the rectum
Description: Skin-subcutaneous fascial flap on the leg is cut out from one side of the perineal wound, and deepithelized, forming a diamond-shaped perineal wound. The cut flap is immersed in the aperture of the pelvis and fixed with single sutures to the remains of levators of the opposite side. The flap width should be 3-4 cm, sufficient to fill the pelvic aperture. On the opposite side of the wound, a skin-subcutaneous fascial flap is cut out on a triangular leg equal to the width of the previously formed diamond-shaped wound. The flap is moved to the center of the wound, additionally filling wound cavity with it, combining the vertex of the triangle with the vertex of the rhombus. The perineal wound is drained through the contraperture. The flap is fixed with separate nodal seams.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Plastic surgery of the pelvic floor and perineal wound with local tissues
Description: Simple layer-by-layer suturing of the sciatic-anal and subcutaneous adipose tissue is performed using nodular sutures. The skin was sewn up with nodular sutures at the discretion of surgeons. The installation of abdominal drainage and/or perineal drainage was left to the discretion of the surgeon.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Plastic surgery of the pelvic floor and perineal wound with mesh endoprosthesis
Description: A mesh allograft with an adhesive coating is inserted into the bottom of the wound, positioned horizontally between the inner surfaces of the ischial bones and vertically between the sacrum and the vagina in women or between the sacrum and the prostate gland in men. The mesh was sewn from behind on both sides of the coccyx or sacrum. From the side, the mesh was attached to the remainder of the levator muscle and from the front to the transverse muscles of the perineum. The installation of abdominal drainage and/or perineal drainage was left to the discretion of the surgeon. The sciatic-anal and subcutaneous fat are sutured using nodular sutures.
Study: NCT06395714

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personnalized physiotherapy
Description: Following completion of the ankle go test, patients in experimental group will receive specific instructions for continuing their rehabilitation, which will be passed on to the physiotherapist responsible for the rehabilitation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual physiotherapy
Description: Following completion of the ankle go test, patients in active comparator group will receive usual physiotherapy
Study: NCT04630626

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simplify Disc
Description: The Simplify Disc is a cervical artificial disc manufactured from polyether ether ketone (PEEK) endplates and a mobile, zirconia-toughened alumina ceramic core.

Intervention type: OTHER
Group type: OTHER
Intervention: ACDF
Description: Historical ACDF control data
Study: NCT04880889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL 3000
Description: capsule 500 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference Pantogar
Description: capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BL3000 Placebo
Description: capsule 500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantogar - Placebo
Description: capsule
Study: NCT06092957

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin-based induction chemotherapy
Description: Cisplatin-based induction chemotherapy will be given every 3 weeks for 3 cycles before radiotherapy including GP, TP, and TPF regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin-based induction chemotherapy
Description: Cisplatin-based induction chemotherapy will be given every 3 weeks for 3 cycles before radiotherapy including GP, TP, and TPF regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin-based induction chemotherapy
Description: Cisplatin-based induction chemotherapy will be given every 3 weeks for 3 cycles before radiotherapy including GP, TP, and TPF regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Full course of PD-1/PD-L1 blockades
Description: a) Camrelizumab 200mg, b) Toripalimab 240mg, or c) Adebrelimab 1200mg will be started on day 1 of induction chemotherapy and given every 3 weeks for up to 12 cycles, or until intolerable toxicity, or disease progression or withdrawal from the treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Full course of PD-1/PD-L1 blockades
Description: a) Camrelizumab 200mg, b) Toripalimab 240mg, or c) Adebrelimab 1200mg will be started on day 1 of induction chemotherapy and given every 3 weeks for up to 12 cycles, or until intolerable toxicity, or disease progression or withdrawal from the treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Full course of PD-1/PD-L1 blockades
Description: a) Camrelizumab 200mg, b) Toripalimab 240mg, or c) Adebrelimab 1200mg will be started on day 1 of induction chemotherapy and given every 3 weeks for up to 12 cycles, or until intolerable toxicity, or disease progression or withdrawal from the treatment.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Reduced-dose IMRT
Description: GTVnx:60Gy/30F/2.0Gy，CTV1:54Gy/30F/1.8Gy，CTV2:48Gy/30F/1.6Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Reduced-dose IMRT
Description: GTVnx:60Gy/30F/2.0Gy，CTV1:54Gy/30F/1.8Gy，CTV2:48Gy/30F/1.6Gy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard-dose IMRT
Description: GTVnx：69.96Gy/33Fr/2.12Gy；CTV1：60.60Gy/33Fr/1.82y；CTV2：54.12Gy/33Fr/1.64Gy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent Chemotherapy
Description: Cisplatin 100mg/m2 every 3 weeks for 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent Chemotherapy
Description: Cisplatin 100mg/m2 every 3 weeks for 2 cycles
Study: NCT05232305

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate Peel
Description: Standard bread and test breads (with added pomegranate peel) to be used in the study will be produced by Asst. Prof. Özlem ÖZPAK AKKUŞ in the Nutrition Principles Laboratory of Toros University. For standard bread, 900 ml of water, 42 fresh yeast, 12 g of salt and 12 g of sunflower oil will be added to 1000 g of sifted whole wheat flour and the prepared bread mixture will be divided into 40 equal parts. To make bread with pomegranate peel added, 1000 g of sifted whole wheat flour, 20 g of pomegranate peel powder, 914 ml of water, 42 g of fresh yeast, 12 g of salt and 12 g of sunflower oil will be added and the prepared bread mixture is divided into 40 equal parts with 500 mg of pomegranate peel powder in each piece).
Study: NCT05137145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: The observation group 1 was given Linaclotide in 1 day combined with 4L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine, and the observation group 2 was given Linaclotide in 1 day combined with 4L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine. observation group 3 was given Linaclotide in 3 day combined with 3L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine. Intestinal cleanliness and the incidence of adverse reactions of patients in each group were compared.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: The observation group 1 was given Linaclotide in 1 day combined with 4L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine, and the observation group 2 was given Linaclotide in 1 day combined with 4L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine. observation group 3 was given Linaclotide in 3 day combined with 3L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine. Intestinal cleanliness and the incidence of adverse reactions of patients in each group were compared.
Study: NCT06627803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol (Oral)
Description: Participants will drink a beverage that will have alcohol or no alcohol. The amount of alcohol consumed will be similar to consuming around 3-4 drinks, with breath alcohol concentration peaking at or around the legal limit for driving (0.08%).
Study: NCT06628024

Intervention type: OTHER
Group type: OTHER
Intervention: Milk
Description: Milk

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoghurt
Description: Yoghurt
Study: NCT06628011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group/training group
Description: We will assess the short-term effects through a 12-week intervention, and its long-term effects after 1-year. Both the intervention group (IG) and control group (CG) will receive two sessions of aerobic interval training at the Exercise Training Clinic, situated at the Department of Psychosis and Rehabilitation, Psychiatry Clinic, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway. One training session consists of 36 minutes of high intensity training (HIT).
Study: NCT05137145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: The observation group 1 was given Linaclotide in 1 day combined with 4L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine, and the observation group 2 was given Linaclotide in 1 day combined with 4L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine. observation group 3 was given Linaclotide in 3 day combined with 3L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine. Intestinal cleanliness and the incidence of adverse reactions of patients in each group were compared.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Polyethylene Glycol Electrolyte Powder
Description: The control group was given Compound Polyethylene Glycol Electrolyte Powder to clear the intestines,
Study: NCT05884957

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Nitric oxide synthase gene
Description: Biochemical assessment of serum nitric oxide level pre and post 5 mg tadalafil therapy in diabetic patients with erectile dysfunction and in normal healthy controls.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Nitric oxide synthase gene
Description: Biochemical assessment of serum nitric oxide level pre and post 5 mg tadalafil therapy in diabetic patients with erectile dysfunction and in normal healthy controls.
Study: NCT05137145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Polyethylene Glycol Electrolyte Powder
Description: The control group was given Compound Polyethylene Glycol Electrolyte Powder to clear the intestines,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Polyethylene Glycol Electrolyte Powder
Description: The control group was given Compound Polyethylene Glycol Electrolyte Powder to clear the intestines,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Polyethylene Glycol Electrolyte Powder
Description: The control group was given Compound Polyethylene Glycol Electrolyte Powder to clear the intestines,
Study: NCT04849000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1209
Description: SHR-1209

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHR-1209 Placebo
Description: SHR-1209 Placebo
Study: NCT05072535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA121-28 tablet B
Description: HA121-28 tablet B 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA121-28 tablet B
Description: HA121-28 tablet B 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA121-28 tablet B
Description: HA121-28 tablet B 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA121-28 tablet B
Description: HA121-28 tablet B 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA121-28 tablet A
Description: HA121-28 tablet A 200 mg